ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
35.58
-0.50%
US Tech 100
18,385.60
0.37%
S&P 500
5,306.04
0.02%
US Dollar vs CAD
1.36462
0.12%
Bitcoin
68,562.47
-1.20%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Genprex Inc (GNPX)

  7. Genprex Inc (GNPX) News

GNPX

Genprex (GNPX)

Genprex Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:GNPX
DateTimeSourceHeadlineSymbolCompany
05/20/20243:35PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:GNPXGenprex Inc
05/15/20243:15PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:GNPXGenprex Inc
05/14/20247:31AMPR Newswire (US)Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa® Immunogene Therapy in Combination with Tecentriq® to Treat Small Cell Lung CancerNASDAQ:GNPXGenprex Inc
05/13/20247:31AMPR Newswire (US)Genprex Announces the Appointment of Jose A. Moreno Toscano as Chairman of the Board of DirectorsNASDAQ:GNPXGenprex Inc
05/09/20247:11AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:GNPXGenprex Inc
05/08/20245:08PMPR Newswire (US)Genprex Announces the Passing of its Co-Founder and Chief Executive Officer, Rodney VarnerNASDAQ:GNPXGenprex Inc
05/01/20247:31AMPR Newswire (US)Genprex to Present and Participate at Upcoming May Investor and Industry ConferencesNASDAQ:GNPXGenprex Inc
04/09/20247:31AMPR Newswire (US)Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual MeetingNASDAQ:GNPXGenprex Inc
04/03/20247:31AMPR Newswire (US)Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa® Therapy in Combination with Tecentriq® to Treat Small Cell Lung CancerNASDAQ:GNPXGenprex Inc
04/02/20247:31AMPR Newswire (US)Genprex Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex® Delivery SystemNASDAQ:GNPXGenprex Inc
03/22/20243:10PMPR Newswire (US)Genprex Announces Closing of $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:GNPXGenprex Inc
03/19/202412:24PMPR Newswire (US)Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:GNPXGenprex Inc
03/19/20247:36AMPR Newswire (US)Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:GNPXGenprex Inc
03/12/20248:01AMPR Newswire (US)Genprex Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa® Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat CancersNASDAQ:GNPXGenprex Inc
03/06/20248:18AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:GNPXGenprex Inc
03/06/20247:30AMPR Newswire (US)Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual MeetingNASDAQ:GNPXGenprex Inc
02/26/20247:45AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:GNPXGenprex Inc
02/21/20243:34PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GNPXGenprex Inc
02/21/20243:32PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GNPXGenprex Inc
02/21/20243:28PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GNPXGenprex Inc
02/14/20241:14PMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:GNPXGenprex Inc
02/07/20247:15AMPR Newswire (US)Genprex Expands Nonclinical Programs into New Therapeutic Indications with Research CollaboratorsNASDAQ:GNPXGenprex Inc
02/06/20246:30AMPR Newswire (US)Genprex to Present at Upcoming BIO CEO & Investor ConferenceNASDAQ:GNPXGenprex Inc
02/05/20247:15AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:GNPXGenprex Inc
02/05/20246:30AMPR Newswire (US)Genprex Announces First Patient Dosed in Phase 2a Expansion of Acclaim-1 Clinical Study of Reqorsa® Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung CancerNASDAQ:GNPXGenprex Inc
02/02/20246:30AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:GNPXGenprex Inc
01/31/20248:00AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:GNPXGenprex Inc
01/31/20247:42AMPR Newswire (US)Genprex Announces 1-for-40 Reverse Stock Split Effective February 2, 2024NASDAQ:GNPXGenprex Inc
01/05/20243:17PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:GNPXGenprex Inc
01/05/20246:00AMPR Newswire (US)Genprex Provides Business Update and Outlook for 2024NASDAQ:GNPXGenprex Inc
 Showing the most relevant articles for your search:NASDAQ:GNPX

Your Recent History

USOTC
ACRL
Atacama Resources (PK)
USOTC
EPAZ
Epazz (PK)
USOTC
CBIA
Canopus Biopharma (PK)
USOTC
CYDY
CytoDyn (QB)
USOTC
KBLB
Kraig Biocraft Laborator... (QB)
USOTC
MWWC
Marketing Worldwide (PK)
USOTC
SAPX
Seven Arts Entertainment (PK)
USOTC
PSRU
Valiant Eagle (PK)
USOTC
SFRX
Seafarer Exploration (PK)
USOTC
CATV
4Cable TV (PK)
USOTC
VXIT
Virexit Technologies (PK)
USOTC
IQST
iQSTEL (QX)
USOTC
KEGS
1812 Brewing (PK)
NASDAQ
FCEL
FuelCell Energy
NASDAQ
TSLA
Tesla
USOTC
HHSE
Hannover House (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved